-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115

Benzinga·08/07/2026 11:02:50
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $95 to $115.